医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

AmbioPharm Inc. Announces New Shanghai Campus Opening and European Executive Team Members

2021年01月07日 PM05:00
このエントリーをはてなブックマークに追加


 

NORTH AUGUSTA, S.C.

AmbioPharm Inc., a worldwide leader in peptide API CDMO services, has recently opened its new Shanghai campus. The new campus adds nearly 50,000 m2 of manufacturing, quality control and administrative space. “We have added 4 new buildings which add to our solid-phase and liquid-phase peptide facilities at our Shanghai production site positioning AmbioPharm as the go-to source for all peptide API needs that our partners have. This is in addition to the manufacturing expansion which was completed at our USA headquarters in mid-2020,” stated Dr. Chris Bai, CEO and co-founder.

Additionally, AmbioPharm has established a new office in Zurich, Switzerland which is headed by Kathleen Noack, VP of European Sales and Marketing. Additionally, Dr. Michael Postlethwaite, Sales Director, has joined the AmbioPharm Europe team also working from this new office. “We are delighted to add two highly experienced seasoned professionals to our European team. Both Ms. Noack and Dr. Postlethwaite come with a wealth of peptide API development knowledge to establish and extend our European partnerships,” says Jim Hampton, Executive VP of GMP Sales and co-founder.

About AmbioPharm Inc.:

AmbioPharm is a leading and innovation-driven company specializing in the development and manufacture of peptides and peptide-related products. With a comprehensive range of services, AmbioPharm produces custom products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide. Headquartered in the United States of America and with locations in Europe, the USA and Asia, AmbioPharm operates internationally with over 14 years of experience and expertise. Further information is available at: http://www.ambiopharm.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20210107005012/en/

CONTACT

AmbioPharm Inc.

Michael Pennington, Ph.D.

mike.pennington@ambiopharm.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Take ‘VOW’ to Protect All Humanity: ‘Vaccinate Our World!’
  • 太平洋電気通信協議会が第44回年次総会の参加募集を発表
  • アビオメッド、ImpellaのPROTECT IVランダム化対照試験に最初の患者を組み入れたことを発表
  • Prestige Biopharma’s New Vaccine Production Centre for Infectious Diseases Including COVID-19
  • Pacific Telecommunications Council Announces the Call for Participation for Its 44th Annual Conference